Ionotropic glutamate receptors in epilepsy: a review focusing on AMPA and NMDA receptors

T Hanada - Biomolecules, 2020 - mdpi.com
It is widely accepted that glutamate-mediated neuronal hyperexcitation plays a causative
role in eliciting seizures. Among glutamate receptors, the roles of N-methyl-D-aspartate …

[HTML][HTML] Behavioral adverse events with brivaracetam, levetiracetam, perampanel, and topiramate: a systematic review

BJ Steinhoff, P Klein, H Klitgaard, C Laloyaux… - Epilepsy & Behavior, 2021 - Elsevier
Purpose To understand the currently available post-marketing real-world evidence of the
incidences of and discontinuations due to the BAEs of irritability, anger, and aggression in …

PERMIT study: a global pooled analysis study of the effectiveness and tolerability of perampanel in routine clinical practice

V Villanueva, W D'Souza, H Goji, DW Kim, C Liguori… - Journal of …, 2022 - Springer
The PER a M panel pooled analys I s of effec T iveness and tolerability (PERMIT) study was
a pooled analysis of data from 44 real-world studies from 17 countries, in which people with …

The broad-spectrum activity of perampanel: state of the art and future perspective of AMPA antagonism beyond epilepsy

F Perversi, C Costa, A Labate, S Lattanzi… - Frontiers in …, 2023 - frontiersin.org
Glutamate is the brain's main excitatory neurotransmitter. Glutamatergic neurons primarily
compose basic neuronal networks, especially in the cortex. An imbalance of excitatory and …

Perampanel as precision therapy in rare genetic epilepsies

A Nissenkorn, G Kluger, S Schubert‐Bast, A Bayat… - …, 2023 - Wiley Online Library
Objective Perampanel, an antiseizure drug with α‐amino‐3‐hydroxy‐5‐methyl‐4‐
isoxazolepropionic acid receptor antagonist properties, may have a targeted effect in genetic …

[HTML][HTML] Efficacy and tolerability of perampanel as a first add-on therapy with different anti-seizure drugs

E Santamarina, V Bertol, V Garayoa… - Seizure, 2020 - Elsevier
Purpose To investigate the efficacy and tolerability of perampanel (PER) when administered
as a first add-on therapy to patients with focal epilepsy or idiopathic generalized epilepsy …

Kainate receptor antagonists: recent advances and therapeutic perspective

P Chałupnik, E Szymańska - International Journal of Molecular Sciences, 2023 - mdpi.com
Since the 1990s, ionotropic glutamate receptors have served as an outstanding target for
drug discovery research aimed at the discovery of new neurotherapeutic agents. With the …

Exploring the evidence for broad-spectrum effectiveness of perampanel: a systematic review of clinical data in generalised seizures

E Trinka, S Lattanzi, K Carpenter, T Corradetti… - CNS drugs, 2021 - Springer
Background The effectiveness of adjunctive perampanel has not been systematically
assessed in seizure types other than its approved indications of focal seizures and primary …

Effectiveness and safety of perampanel as early add-on treatment in patients with epilepsy and focal seizures in the routine clinical practice: Spain prospective study …

JA Jaramillo, JCE María, JMG Úbeda, ÓV López… - Epilepsy & Behavior, 2020 - Elsevier
Objective Perampanel (PER) has been shown to be effective as an adjunctive therapy for
controlling refractory focal-onset seizures (FOS). However, the information as early add-on …

Targeting ionotropic glutamate receptors in the treatment of epilepsy

R Celli, F Fornai - Current Neuropharmacology, 2021 - ingentaconnect.com
Background: A dysfunction in glutamate neurotransmission is critical for seizure. Glutamate
is the major excitatory drive in the cerebral cortex, where seizures occur. Glutamate acts via …